PURPOSE: High-frequency microsatellite instability (MSI-H) occurs frequently in colorectal cancers and some other tumor types, but is very uncommon in breast cancer. In the earlier study devoted to microsatellite analysis of allelic imbalances, the authors accidentally detected several MSI-H tumors in patients with the bilateral form of breast cancer (biBC). The present study was designed to examine this unexpected phenomenon in more detail. METHODS: All DNA samples were tested by the standard panel of MSI-specific markers BAT25, BAT26, BAT40, D5S346, and D17S250. If the tumor was unstable for at least one marker, or PCR amplification was not successful for any of the listed above loci, the analysis of additional five dinucleotide markers (D1S225, D11S4167, D22S272, D22S1166, and D3S3527) was performed. Tumors showing instability in > or = 30% loci were classified as MSI-H. RESULTS: In biBC group, MSI-H status was detected in 6/60 (10%) contralateral tumors, but in 0/50 (0%) first malignancies (P = 0.021) and only in 1/22 (5%) synchronous biBC (P = 0.434). None of 52 unilateral breast cancers showed MSI-H status. Shifts of mononucleotide markers were revealed in four second carcinomas from biBC patients but in none of the breast tumors from other categories. CONCLUSIONS: MSI-H is detected with a noticeable frequency in bilateral but not in unilateral breast cancers. Preferable occurrence of MSI-H in second metachronous tumors from biBC patients allows to hypothesize that the development of some contralateral breast neoplasms is casually related to the adjuvant treatment of the initial malignancy.
PURPOSE: High-frequency microsatellite instability (MSI-H) occurs frequently in colorectal cancers and some other tumor types, but is very uncommon in breast cancer. In the earlier study devoted to microsatellite analysis of allelic imbalances, the authors accidentally detected several MSI-H tumors in patients with the bilateral form of breast cancer (biBC). The present study was designed to examine this unexpected phenomenon in more detail. METHODS: All DNA samples were tested by the standard panel of MSI-specific markers BAT25, BAT26, BAT40, D5S346, and D17S250. If the tumor was unstable for at least one marker, or PCR amplification was not successful for any of the listed above loci, the analysis of additional five dinucleotide markers (D1S225, D11S4167, D22S272, D22S1166, and D3S3527) was performed. Tumors showing instability in > or = 30% loci were classified as MSI-H. RESULTS: In biBC group, MSI-H status was detected in 6/60 (10%) contralateral tumors, but in 0/50 (0%) first malignancies (P = 0.021) and only in 1/22 (5%) synchronous biBC (P = 0.434). None of 52 unilateral breast cancers showed MSI-H status. Shifts of mononucleotide markers were revealed in four second carcinomas from biBCpatients but in none of the breast tumors from other categories. CONCLUSIONS:MSI-H is detected with a noticeable frequency in bilateral but not in unilateral breast cancers. Preferable occurrence of MSI-H in second metachronous tumors from biBCpatients allows to hypothesize that the development of some contralateral breast neoplasms is casually related to the adjuvant treatment of the initial malignancy.
Authors: E N Imyanitov; A V Togo; E N Suspitsin; M Y Grigoriev; K M Pozharisski; E A Turkevich; K P Hanson; N K Hayward; G Chenevix-Trench; C Theillet; M F Lavin Journal: Cancer Lett Date: 2000-06-01 Impact factor: 8.679
Authors: Konstantin G Buslov; Aglaya G Iyevleva; Elena V Chekmariova; Evgeny N Suspitsin; Alexandr V Togo; Ekatherina Sh Kuligina; Anna P Sokolenko; Dmitry E Matsko; Elena A Turkevich; Yulia R Lazareva; Oleg L Chagunava; Elena M Bit-Sava; Vladimir F Semiglazov; Peter Devilee; Cees Cornelisse; Kaido P Hanson; Evgeny N Imyanitov Journal: Int J Cancer Date: 2005-04-20 Impact factor: 7.396
Authors: Evgeny N Imyanitov; Evgeny N Suspitsin; Maxim Yu Grigoriev; Alexandr V Togo; Ekatherina Sh Kuligina; Evgeniya V Belogubova; Kazymir M Pozharisski; Elena A Turkevich; Carmen Rodriquez; Cees J Cornelisse; Kaido P Hanson; Charles Theillet Journal: Int J Cancer Date: 2002-08-10 Impact factor: 7.396
Authors: C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava Journal: Cancer Res Date: 1998-11-15 Impact factor: 12.701
Authors: V F Semiglazov; E E Topuzov; J L Bavli; V M Moiseyenko; O A Ivanova; I K Seleznev; A A Orlov; N Y Barash; O M Golubeva; O F Chepic Journal: Ann Oncol Date: 1994-09 Impact factor: 32.976
Authors: Tasha R Smith; Edward A Levine; Rita I Freimanis; Steven A Akman; Glenn O Allen; Kimberly N Hoang; Wen Liu-Mares; Jennifer J Hu Journal: Carcinogenesis Date: 2008-08-13 Impact factor: 4.944
Authors: Tasha R Smith; Wen Liu-Mares; Beth O Van Emburgh; Edward A Levine; Glenn O Allen; Jeff W Hill; Isildinha M Reis; Laura A Kresty; Mark D Pegram; Mark S Miller; Jennifer J Hu Journal: Carcinogenesis Date: 2011-06-23 Impact factor: 4.944
Authors: Carlo Fremd; Mario Hlevnjak; Marc Zapatka; Inka Zoernig; Niels Halama; Nino Fejzibegovic; Verena Thewes; Peter Lichter; Peter Schirmacher; Matthias Kloor; Frederik Marmé; Florian Schütz; Zeynep Kosaloglu; Hans Peter Sinn; Dirk Jäger; Andreas Schneeweiss Journal: Breast Care (Basel) Date: 2018-11-14 Impact factor: 2.860
Authors: Katie T Huang; Thomas Mikeska; Jason Li; Elena A Takano; Ewan K A Millar; Peter H Graham; Samantha E Boyle; Ian G Campbell; Terence P Speed; Alexander Dobrovic; Stephen B Fox Journal: BMC Cancer Date: 2015-10-09 Impact factor: 4.430